Compare ClearPoint Neuro Inc (CLPT) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Dollar General Corp. — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Dollar General Corp. trades at $120.07 (market cap $27.00B). The key difference: Dollar General Corp. is far larger — about 60.8× ClearPoint Neuro Inc's market cap, and Dollar General Corp. pays a 1.93% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | DG | |
|---|---|---|
Market Cap | $444.14M | $27.00B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $156.26 |
52-Week Low | $8.66 | $95.94 |
Enterprise Value | $478.72M | $41.45B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Dollar General (DG) trades at $126.59, down 0.69% on the day, with strong technical momentum indicated by bullish moving averages and oversold RSI conditions. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.00 exceeding expectations of $1.89, while maintaining solid profitability metrics including 18.91% ROE. Recent cash flow trends show improvement with 2025 net cash flow of $395 million, and the balance sheet reflects declining debt-to-asset ratios from 22.73% to 20.03% year-over-year.
The outlook remains positive with analyst consensus favoring Buy ratings (52%) and a $128.45 price target offering modest upside. Key opportunities include consumer trade-down benefits and margin improvement, while risks involve competition from Walmart and Amazon, market saturation concerns, and ongoing cost pressures. The stock presents a value proposition with attractive P/S (0.65) and P/E (17.91) multiples relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
